BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/11 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Baird Christopher Raymond Price target Neutral 6% $90.05
Brean Murray Jonathan Aschoff Price target Buy
Deutsche Bank Robyn Karnauskas Price target Buy
Jefferies Eun Yang Price target Hold
Leerink Howard Liang Price target Market outperform
Needham Mark Monane Price target Buy
Raymond raised his target to $85 from $76 after Alexion reported 4Q10 diluted non-GAAP EPS of $0.51, beating consensus by a penny, and gave FY11 non-GAAP diluted EPS and revenue guidance of $2.10-$2.25 and $715-$735M, respectively. The Street was expecting $715M. Raymond raised his FY11 revenue estimates to $743M. He noted the company said it plans to submit regulatory applications in the U.S. and EU for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS) in mid-2011. Alexion already markets the humanized mAb targeting complement 5 (C5) for paroxysmal...

Read the full 1225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >